Plain-English translation of NCT07370688 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether ferric carboxymaltose, an iron treatment given through an IV, can help patients feel better after heart valve replacement surgery. Many people who need this surgery also have iron deficiency, which can make them feel tired and weak even after the valve is fixed. Researchers want to see if treating the iron deficiency helps patients recover better and enjoy their daily lives more.
After heart valve replacement surgery, some patients still struggle with fatigue and limited energy, even though their heart valve is now working properly. This medication might help by addressing iron deficiency, which is known to affect how well people feel and function after surgery.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll be randomly assigned to either receive iron infusions or standard care (no iron) after your valve replacement surgery. If you receive the medication, you'll get 1 to 3 infusions over 12 weeks. You'll complete questionnaires about your quality of life and take a 6-minute walk test at the start and again 24 weeks after surgery. During follow-up visits, the research team will check your blood work and monitor your overall health.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Netherlands